Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis.
Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis.
复制标题
DOI：
10.3349/ymj.2016.57.6.1324
复制
发表时间：
2016-11
影响因子：
2.4
通讯作者：
Kim IJ
中科院分区：
文献类型：
--
作者：
Suh S;Pak K;Seok JW;Kim IJ
甲状腺癌是最常见的内分泌肿瘤，近三十年来在世界范围内发病率呈持续上升趋势。我们的目的是评估甲状腺癌结节扩散（ENE）的预后价值。我们对MEDLINE（从开始到2014年6月）和EMBASE（从开始到2014年6月）进行了系统检索，以查找英文出版物。纳入标准是报告了ENE在甲状腺癌中的预后价值的甲状腺癌研究。排除综述、摘要和编辑材料，删除重复数据。两位作者独立进行了数据提取。6项研究（包括1830例患者）有资格入选本研究。纳入荟萃分析的所有患者均患有甲状腺乳头状癌（PTC）。基于3项研究分析了无复发生存期。复发的合并风险比为2.01 [95%置信区间（CI）1.19-3.40，p=0.009]。基于3项研究（973例患者）分析了疾病特异性生存期。PTC伴ENE患者的死亡风险高3.37倍（95% CI 1.55-7.32，p=0.002）。ENE应被认为是甲状腺癌预后不良的标志物;这些知识可能会改善个体患者的管理。这可能有助于制定适当的消融治疗计划，并从治疗开始就进行定制的患者随访。
Thyroid cancer is the most common endocrine cancer and its incidence has continuously increased in the last three decades all over the world. We aimed to evaluate the prognostic value of extranodal extension (ENE) of thyroid cancer. We performed a systematic search of MEDLINE (from inception to June 2014) and EMBASE (from inception to June 2014) for English-language publication. The inclusion criteria were studies of thyroid cancer that reported the prognostic value of ENE in thyroid cancer. Reviews, abstracts, and editorial materials were excluded, and duplicate data were removed. Two authors performed the data extraction independently. 6 studies including 1830 patients were eligible for inclusion in the study. All patients included in the meta-analysis had papillary thyroid cancer (PTC). Recurrence-free survival was analyzed based on 3 studies. The pooled hazard ratio for recurrence was 2.01 [95% confidence interval (CI) 1.19–3.40, p=0.009]. Disease-specific survival was analyzed based on 3 studies with 973 patients. Patients of PTC with ENE showed 3.37-fold higher risk of death from the disease (95% CI 1.55–7.32, p=0.002). ENE should be considered to be a poor prognostic marker in thyroid cancer; such knowledge might improve the management of individual patients. This might facilitate the planning of appropriate ablation therapy and tailored patient follow-up from the beginning of treatment.
登录
查看更多内容
影响因子：
5.9
作者：
MAZZAFERRI, EL;JHIANG, SM
通讯作者：
JHIANG, SM
影响因子：
3.7
作者：
Wang LY;Palmer FL;Nixon IJ;Tuttle RM;Shah JP;Patel SG;Shaha AR;Ganly I
通讯作者：
Ganly I
影响因子：
6.6
作者：
Lango, Miriam;Flieder, Douglas;Ridge, John A.
通讯作者：
Ridge, John A.
影响因子：
6.6
作者：
Clain, Jason B.;Scherl, Sophie;Urken, Mark L.
通讯作者：
Urken, Mark L.
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG